ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

2023 COPD Guidelines Update

Antonio Anzueto

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

COPD Exacerbations: if Not, What Else?

Temple Lung Center

J. Bon

CHEST 2024 Insights: Breathing New Life - Trailblazing Trials in Gro…

Temple Lung Center

P. Rali

Updates in Pulmonary Function Testing

National Jewish Health

M. Mohning

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

Bronchiectasis: What's New and What's Next?

3rd Advanced Lung Disease: Novel Therapies and Controversies Conference

S. Devarajan

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF in Women

Scripps Health

B. Borlaug

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

CHEST Insights 2024: Determining the Impact of COVID-19 Infection on…

CHEST Annual Meeting Insights

A. Arumairaj

Updates in Chronic Obstructive Pulmonary Disease

Duke Health

Z. Hager

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Alpha One - Antitrypsin Deficiency: More Common Than You Think

Kyle Hogarth